Krop IE - Search Results

1

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.

Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. Tolaney SM, et al. Among authors: krop ie. Cancer Med. 2014 Apr;3(2):293-9. doi: 10.1002/cam4.164. Epub 2014 Jan 27. Cancer Med. 2014. PMID: 24464780 Free PMC article. Clinical Trial.

2

Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.

Krop I, Maguire P, Lahti-Domenici J, Lodeiro G, Richardson A, Johannsdottir HK, Nevanlinna H, Borg A, Gelman R, Barkardottir RB, Lindblom A, Polyak K. Krop I, et al. Cancer Res. 2003 May 1;63(9):2024-7. Cancer Res. 2003. PMID: 12727813

3

Ovarian suppression for breast cancer: an effective treatment in search of a home.

Krop IE, Winer EP. Krop IE, et al. J Clin Oncol. 2005 Sep 1;23(25):5869-72. doi: 10.1200/JCO.2005.06.002. Epub 2005 Aug 8. J Clin Oncol. 2005. PMID: 16087947 No abstract available.

4

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Segara D, et al. Among authors: krop ie. J Surg Oncol. 2007 Nov 1;96(6):474-80. doi: 10.1002/jso.20856. J Surg Oncol. 2007. PMID: 17640031 Clinical Trial.

5

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: krop ie. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.

6

Ten years of HER2-directed therapy: still questions after all these years.

Krop IE, Winer EP. Krop IE, et al. Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8. Breast Cancer Res Treat. 2009. PMID: 18463974 No abstract available.

7

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE. Tolaney SM, et al. Among authors: krop ie. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.

8

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Krop IE, et al. J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421541 Clinical Trial.

9

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Flores LM, et al. Among authors: krop ie. Br J Cancer. 2010 May 11;102(10):1495-502. doi: 10.1038/sj.bjc.6605676. Br J Cancer. 2010. PMID: 20461092 Free PMC article.

10

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE. Mayer EL, et al. Among authors: krop ie. Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Clin Cancer Res. 2010. PMID: 20634194 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters